Management of breast cancer patients with BRCA gene mutations in Jordan: perspectives and challenges.

Q2 Medicine Hospital practice (1995) Pub Date : 2023-10-01 Epub Date: 2023-11-16 DOI:10.1080/21548331.2023.2266019
Hikmat Abdel-Razeq, Salah Abbasi, Ghadeer Abdeen, Hazem Abdulelah, Jamil Debs, Sarah Al Masri, Majdi H Aljadayeh, Abdalla Awidi
{"title":"Management of breast cancer patients with <i>BRCA</i> gene mutations in Jordan: perspectives and challenges.","authors":"Hikmat Abdel-Razeq, Salah Abbasi, Ghadeer Abdeen, Hazem Abdulelah, Jamil Debs, Sarah Al Masri, Majdi H Aljadayeh, Abdalla Awidi","doi":"10.1080/21548331.2023.2266019","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This paper explores and discusses local challenges oncologists face for diagnosing and managing breast cancer patients with BRCA gene mutations in Jordan.</p><p><strong>Methods: </strong>A task force involving key opinion leaders, experts in the management of breast cancer, and stakeholders in healthcare systems where genetic testing is available in Jordan discussed current evidence and local real-life practice. The task force then formulated recommendations to achieve better patient outcomes and satisfaction based on evidence-based medicine and their clinical experience in BRCA-mutated breast cancer management.</p><p><strong>Results and conclusion: </strong>Eligibility of patients for genetic testing, physician acceptance and willingness to integrate genetic testing into routine practice is encouraging but remains restricted by testing availability and financial coverage. Until more data is available, genetic testing should be targeted for breast cancer patients based on tumor subtypes, as well as family and personal history of cancer, as per international guidelines. Whenever possible, genetic testing should aim to detect all actionable genes through a multigene panel including BRCA1/2. Major challenges faced in clinical practice in Jordan include fear of genetic discrimination and social stigmatization, as well as hesitancy toward risk-reducing surgery. Pre-testing counseling is therefore critical to promote acceptance of genetic testing. Since geneticists are in short supply in Jordan, genetic counseling can be offered through a specially trained genetic counselor or through a hybrid system that includes oncologist-based counselling. In addition to cancer prevention, germline genetic testing may assist in the selection of specific anti-cancer therapy, such as PARP inhibitors, in patients with BRCA1/2 mutation. Nationwide initiatives are also needed to ensure access to PARP inhibition therapy and provide financial coverage for genetic screening, mastectomies and reconstructive surgery across Jordan.</p>","PeriodicalId":35045,"journal":{"name":"Hospital practice (1995)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hospital practice (1995)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21548331.2023.2266019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/16 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: This paper explores and discusses local challenges oncologists face for diagnosing and managing breast cancer patients with BRCA gene mutations in Jordan.

Methods: A task force involving key opinion leaders, experts in the management of breast cancer, and stakeholders in healthcare systems where genetic testing is available in Jordan discussed current evidence and local real-life practice. The task force then formulated recommendations to achieve better patient outcomes and satisfaction based on evidence-based medicine and their clinical experience in BRCA-mutated breast cancer management.

Results and conclusion: Eligibility of patients for genetic testing, physician acceptance and willingness to integrate genetic testing into routine practice is encouraging but remains restricted by testing availability and financial coverage. Until more data is available, genetic testing should be targeted for breast cancer patients based on tumor subtypes, as well as family and personal history of cancer, as per international guidelines. Whenever possible, genetic testing should aim to detect all actionable genes through a multigene panel including BRCA1/2. Major challenges faced in clinical practice in Jordan include fear of genetic discrimination and social stigmatization, as well as hesitancy toward risk-reducing surgery. Pre-testing counseling is therefore critical to promote acceptance of genetic testing. Since geneticists are in short supply in Jordan, genetic counseling can be offered through a specially trained genetic counselor or through a hybrid system that includes oncologist-based counselling. In addition to cancer prevention, germline genetic testing may assist in the selection of specific anti-cancer therapy, such as PARP inhibitors, in patients with BRCA1/2 mutation. Nationwide initiatives are also needed to ensure access to PARP inhibition therapy and provide financial coverage for genetic screening, mastectomies and reconstructive surgery across Jordan.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
约旦乳腺癌症BRCA基因突变患者的管理:前景和挑战。
背景:本文探讨并讨论了约旦肿瘤学家在诊断和管理BRCA基因突变的癌症患者方面面临的当地挑战,约旦可以进行基因检测的医疗保健系统的利益相关者讨论了当前的证据和当地的实际做法。然后,该工作组根据循证医学和他们在BRCA突变的癌症治疗方面的临床经验,制定了实现更好患者结果和满意度的建议。结果和结论:患者进行基因检测的资格、医生的接受程度以及将基因检测纳入常规实践的意愿令人鼓舞,但仍受到检测可用性和财务覆盖范围的限制。在获得更多数据之前,应根据国际指南,根据肿瘤亚型以及癌症家族和个人病史,针对癌症乳腺癌患者进行基因检测。只要可能,基因检测应旨在通过包括BRCA1/2在内的多基因小组检测所有可操作的基因。约旦临床实践中面临的主要挑战包括对基因歧视和社会污名化的恐惧,以及对降低风险手术的犹豫。因此,测试前咨询对于促进接受基因测试至关重要。由于约旦的遗传学家供不应求,可以通过受过专门培训的遗传顾问或包括肿瘤学家咨询在内的混合系统提供遗传咨询。除了癌症预防外,种系基因检测可能有助于BRCA1/2突变患者选择特定的抗癌疗法,如PARP抑制剂。还需要在全国范围内采取举措,确保获得PARP抑制治疗,并为约旦各地的基因筛查、乳房切除术和重建手术提供资金保障。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Hospital practice (1995)
Hospital practice (1995) Medicine-Medicine (all)
CiteScore
2.80
自引率
0.00%
发文量
54
期刊最新文献
An insight into the updated pharmacotherapy of metabolic-associated fatty liver disease (MAFLD) or metabolic dysfunction-associated steatohepatitis (MASH) in lean individuals: a review. Chest tube size selection for pleural effusion: from the perspective of thoracic surgeons and pulmonologists. Prescription for crisis: the compounding effect of community drug shortages on Lebanon's healthcare system. Outcomes and complications of heart failure with iron deficiency anemia: a nationwide analysis. Benign acute myositis in an adult: case-based review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1